AmgenAMGNEarnings & Financial Report
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics.
AMGN Q4 2025 Key Financial Metrics
Revenue
$9.9B
Gross Profit
$6.9B
Operating Profit
$2.7B
Net Profit
$1.3B
Gross Margin
69.8%
Operating Margin
27.6%
Net Margin
13.5%
YoY Growth
8.6%
EPS
$2.45
Financial Flow
Amgen Q4 2025 Financial Summary
Amgen reported revenue of $9.9B for Q4 2025, with a net profit of $1.3B (13.5% margin). Cost of goods sold was $3.0B, operating expenses totaled $4.2B.
Key Financial Metrics
| Total Revenue | $9.9B |
|---|---|
| Net Profit | $1.3B |
| Gross Margin | 69.8% |
| Operating Margin | 27.6% |
| Report Period | Q4 2025 |
Amgen Annual Revenue by Year
Amgen annual revenue history includes year-by-year totals (for example, 2025 revenue was $36.8B).
| Year | Annual Revenue |
|---|---|
| 2025 | $36.8B |
| 2024 | $33.4B |
| 2023 | $28.2B |
| 2022 | $26.3B |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $7.45B | $8.39B | $8.50B | $9.09B | $8.15B | $9.18B | $9.56B | $9.87B |
| YoY Growth | 22.0% | 20.1% | 23.2% | 10.9% | 9.4% | 9.4% | 12.4% | 8.6% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $92.98B | $90.91B | $90.88B | $91.84B | $89.37B | $87.90B | $90.14B | $90.59B |
| Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Equity | $5.02B | $5.92B | $7.53B | $5.88B | $6.21B | $7.43B | $9.62B | $8.66B |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $689.0M | $2.46B | $3.57B | $4.77B | $1.39B | $2.28B | $4.68B | $1.60B |
Other Health Care Companies
ABBV
AbbVie
Revenue
$15.8B
Net Profit
$186.0M
BIIB
Biogen
Revenue
$2.3B
Net Profit
$-48.9M
GILD
Gilead Sciences
Revenue
$7.8B
Net Profit
$3.1B
INCY
Incyte
Revenue
$1.5B
Net Profit
$299.3M
MRNA
Moderna
Revenue
$1.0B
Net Profit
$-200.0M
REGN
Regeneron Pharmaceuticals
Revenue
$3.9B
Net Profit
$844.6M
VRTX
Vertex Pharmaceuticals
Revenue
$3.2B
Net Profit
$1.2B
ABT
Abbott Laboratories
Revenue
$11.4B
Net Profit
$1.6B
A
Agilent Technologies
Revenue
$1.9B
Net Profit
$434.0M
ALGN
Align Technology
Revenue
$995.7M
Net Profit
$56.8M